Niacin (nicotinic acid)
Metabolic Health · B3 / lipid modifier
Tier B-
High-risk evidence profile
Bottom line
Read Off Label grades Niacin (nicotinic acid) as B- (5.8/10) based on strong evidence, moderate benefit magnitude, and a med-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
Niacin's Lp(a) niche is now being eclipsed by Lp(a)-targeted siRNA/ASO/oral agents (olpasiran, pelacarsen, lepodisiran, zerlasiran, muvalaplin) which lower Lp(a) 54-92% in trials.
Studied, labeled, or reported-use context: 1. — Rx (Niaspan extended release); OTC; not individualized guidance.
What the evidence says
Niacin's Lp(a) niche is now being eclipsed by Lp(a)-targeted siRNA/ASO/oral agents (olpasiran, pelacarsen, lepodisiran, zerlasiran, muvalaplin) which lower Lp(a) 54-92% in trials. 'Flush-free' inositol hexanicotinate does not have the lipid-modifying effect of true niacin. HPS2-THRIVE 2014 largely ended routine use for CV outcomes.
Mechanism
Inhibits hepatic DGAT2 (VLDL assembly); raises HDL, lowers LDL, triglycerides, Lp(a) — the latter was one of the few tools available pre-2025; not to be confused with nicotinamide (which lacks lipid effects)
Studied, labeled, or reported dose & route
1.5-3 g/day PO divided with food in lipid trials; tolerability protocols used gradual titration and sometimes aspirin coadministration to reduce flushing
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Niacin (nicotinic acid)'s effects?
- Read Off Label rates the evidence for Niacin (nicotinic acid) as Strong and the benefit magnitude as moderate, producing an overall grade of B- (5.8/10). Niacin's Lp(a) niche is now being eclipsed by Lp(a)-targeted siRNA/ASO/oral agents (olpasiran, pelacarsen, lepodisiran, zerlasiran, muvalaplin) which lower Lp(a) 54-92% in trials.
- What safety findings are reported for Niacin (nicotinic acid)?
- Niacin (nicotinic acid) has a med-high risk profile in the database. Med-High (intense flushing; hepatotoxicity — especially sustained-release forms; gout flares; glucose elevation; itching) Legal status: Rx (Niaspan extended release); OTC (immediate release / 'flush-free' inositol hexanicotinate — largely inactive on lipids).
- What does the low Safety score for Niacin (nicotinic acid) represent?
- The Safety score is 3.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Niacin (nicotinic acid)?
- 1.5-3 g/day PO divided with food in lipid trials; tolerability protocols used gradual titration and sometimes aspirin coadministration to reduce flushing This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Niacin (nicotinic acid) work?
- Inhibits hepatic DGAT2 (VLDL assembly); raises HDL, lowers LDL, triglycerides, Lp(a) — the latter was one of the few tools available pre-2025; not to be confused with nicotinamide (which lacks lipid effects)
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.